… of CAR T cells in B cell malignancies to other hematological and solid cancer types are …
Tisagenlecleucel and axicabtagen-ciloleucel were the first two cellular cancer immunotherapies …

… of T cell immunity by B cell-based cancer vaccines. Numerous studies have investigated
the nature of TB cell interactions, but those studies mainly focused in the T cell-dependent …

… by adoptive transfer of CTLA4-bearing T reg cells to prevent autoimmunity induced by
CTLA4-deficient T cells that had been transferred to T cell- and B cell-deficient mice (Rag –/– mice…

… Another group at Memorial Sloan-Kettering Cancer Center reported that five relapsed B
cell ALL patients with persistent morphological disease or minimal residual disease positive (…

… Blinatumomab is designed to target B cell-derived malignancies … T cells to CD19-positive
cell lines was demonstrated and was later demonstrated to facilitate elimination of B cells from …

… promising approach for cancer therapy. Here, we report that murine and human B cells with
a … for bifunctional cancer immunotherapy that combines B cell–mediated T-cell activation and …

… CD19 proteins, such as B-cell acute leukemia and large B-cell lymphoma. The drugs … rate
in non-small cell cancers, and KEYNOTE results showed that Pembrolizumab improved overall …

… Importantly, the involvement of B cells in cancer immunotherapy has been … role of B cells
in antitumor immunity and discusses their therapeutic implications in cancer immunotherapy. …

… of six immune cell types (B cells, CD4 T cells, CD8 T cells, neutrophil, macrophage, and
dendritic … The same phenomenon holds for renal clear cell cancer, where tumors with high TIM3 …

… immunotherapies against melanoma, non–small cell lung cancer (NSCLC) and renal cell
cancer … The ICOS-ICOS-L interaction can also induce the excretion of antibodies by B cells. It …